1. Home
  2. XPON vs PHIO Comparison

XPON vs PHIO Comparison

Compare XPON & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expion360 Inc.

XPON

Expion360 Inc.

HOLD

Current Price

$0.56

Market Cap

7.8M

Sector

Technology

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.20

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPON
PHIO
Founded
2016
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
14.6M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
XPON
PHIO
Price
$0.56
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.67
AVG Volume (30 Days)
198.1K
447.5K
Earning Date
03-17-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
94.63
N/A
EPS
N/A
N/A
Revenue
$9,651,870.00
N/A
Revenue This Year
$61.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
71.59
N/A
52 Week Low
$0.58
$0.81
52 Week High
$5.50
$4.19

Technical Indicators

Market Signals
Indicator
XPON
PHIO
Relative Strength Index (RSI) 29.86 52.26
Support Level N/A $1.01
Resistance Level $0.95 $1.21
Average True Range (ATR) 0.05 0.08
MACD -0.01 0.00
Stochastic Oscillator 3.47 71.15

Price Performance

Historical Comparison
XPON
PHIO

About XPON Expion360 Inc.

Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: